A trend for improved OS with bevacizumab was only evident for the patients with BRAF mutant melanomas (HR = 0.80; CI 0.57–1.13; P = 0.21, Figure 3C) and not seen in the patients with BRAF wild-type melanomas (HR = 1.17; CI 0.82–1.61; P = 0.34, Figure 3E). The gene discussed is BRAF; the disease is melanoma.